MARKET

LIMNW

LIMNW

Liminatus Pharma
NASDAQ
0.0400
0.00
0.00%
Opening 09:30 04/01 EDT
OPEN
--
PREV CLOSE
0.0400
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.4700
52 WEEK LOW
0.0300
MARKET CAP
--
P/E (TTM)
-0.4592
1D
5D
1M
3M
1Y
5Y
1D
Liminatus Pharma FY25 net loss widens to $10.2 million; operating loss narrows to $3 million
Reuters · 18h ago
Weekly Report: what happened at LIMNW last week (0323-0327)?
Weekly Report · 2d ago
Weekly Report: what happened at LIMNW last week (0316-0320)?
Weekly Report · 03/23 10:37
Liminatus Pharma plans Phase 1 trial of CD47 antibody IBA101 in lung cancer
Reuters · 03/17 12:08
LIMINATUS PHARMA ANNOUNCES PLANNED PHASE 1 CLINICAL TRIAL OF IBA101, A NEXT-GENERATION CD47 BLOCKING ANTIBODY
Reuters · 03/17 12:08
Weekly Report: what happened at LIMNW last week (0309-0313)?
Weekly Report · 03/16 10:36
Weekly Report: what happened at LIMNW last week (0302-0306)?
Weekly Report · 03/09 10:36
Liminatus Pharma Cuts Shareholder Meeting Quorum to One-Third
Reuters · 03/04 21:17
More
About LIMNW
Iris Acquisition Corp is a Cayman Islands-based blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any business nor generates any revenues.

Webull offers Iris Acquisition Corp stock information, including NASDAQ: LIMNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIMNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIMNW stock methods without spending real money on the virtual paper trading platform.